BR112012015656A2 - composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas - Google Patents

composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas

Info

Publication number
BR112012015656A2
BR112012015656A2 BR112012015656A BR112012015656A BR112012015656A2 BR 112012015656 A2 BR112012015656 A2 BR 112012015656A2 BR 112012015656 A BR112012015656 A BR 112012015656A BR 112012015656 A BR112012015656 A BR 112012015656A BR 112012015656 A2 BR112012015656 A2 BR 112012015656A2
Authority
BR
Brazil
Prior art keywords
dione
methods
quinolin
pyrrolo
indol
Prior art date
Application number
BR112012015656A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher A Lee
David P Reed
Jian-Xie Chen
John C Kane
Martin P Redmon
Neil R Barnes
Original Assignee
Arquile Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arquile Inc filed Critical Arquile Inc
Publication of BR112012015656A2 publication Critical patent/BR112012015656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012015656A 2009-12-23 2010-12-21 composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas BR112012015656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Publications (1)

Publication Number Publication Date
BR112012015656A2 true BR112012015656A2 (pt) 2016-05-10

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015656A BR112012015656A2 (pt) 2009-12-23 2010-12-21 composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN102834097B (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TWI506026B (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
US9180099B2 (en) * 2011-07-07 2015-11-10 Arqule Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
DK3665176T3 (da) * 2017-08-11 2024-03-25 Actuate Therapeutics Inc Faste former af 3-(5-fluorbenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrol-2,5-dion
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024513502A (ja) * 2021-04-07 2024-03-25 ユリカ セラピューティクス インコーポレイテッド Ｕｒａｔ１阻害剤、医薬組成物及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
EP1242420A2 (en) * 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
SI1846406T1 (sl) 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002807A2 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法

Also Published As

Publication number Publication date
NZ628087A (en) 2016-02-26
CO6561823A2 (es) 2012-11-15
EP3081567A3 (en) 2016-11-16
WO2011079142A2 (en) 2011-06-30
PH12012501293A1 (en) 2013-01-07
MY169232A (en) 2019-03-19
RU2012131344A (ru) 2014-01-27
US8871933B2 (en) 2014-10-28
KR20160121602A (ko) 2016-10-19
US8552192B2 (en) 2013-10-08
JP2016041712A (ja) 2016-03-31
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
ZA201204759B (en) 2014-03-26
US20140031551A1 (en) 2014-01-30
TW201141865A (en) 2011-12-01
AU2015243015B2 (en) 2017-02-02
WO2011079142A3 (en) 2011-11-24
EP3081567A2 (en) 2016-10-19
MY156701A (en) 2016-03-15
CN104910159A (zh) 2015-09-16
HK1215025A1 (zh) 2016-08-12
JP2013515737A (ja) 2013-05-09
AU2010336533B2 (en) 2015-09-10
US9499540B2 (en) 2016-11-22
EP2515904A2 (en) 2012-10-31
US20160024076A1 (en) 2016-01-28
RU2556205C2 (ru) 2015-07-10
TW201542546A (zh) 2015-11-16
AU2010336533B9 (en) 2015-10-08
NZ600800A (en) 2014-10-31
EP2515904A4 (en) 2013-07-03
CN102834097B (zh) 2015-06-17
KR101669707B1 (ko) 2016-10-27
MX2012007259A (es) 2015-05-15
AU2015243015A1 (en) 2015-11-05
AU2010336533A1 (en) 2012-07-12
SG181927A1 (en) 2012-07-30
PH12014500310A1 (en) 2015-09-28
TWI557125B (zh) 2016-11-11
US20110160242A1 (en) 2011-06-30
TW201643163A (zh) 2016-12-16
CN102834097A (zh) 2012-12-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
BR112012015656A2 (pt) composições de pirroloquinolinil-pirrolidina-2,5-diona purificada e métodos para preparar e utilizar as mesmas
PH12015501678B1 (en) Inhibitors of influenza viruses replication
NZ600430A (en) Spiro-oxindole mdm2 antagonists
PH12012501055A1 (en) Triazolopyridines
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
WO2010093789A3 (en) A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lh-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
TN2012000595A1 (en) Substituted triazolopyridines
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
GEP20135806B (en) Lactams as beta secretase inhibitors
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2012014918A (es) Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
AR084832A1 (es) Derivado cristalino de oxazina
MX2010009147A (es) Derivados de pirrolidinilo y usos de los mismos.
ATE522531T1 (de) Indolylpyrrolidine zur behandlung von krebs
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2009109973A3 (en) Compounds and methods of treating obesity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.